Artiva Biotherapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Artiva Biotherapeutics (ARTV).

Price Target Range — 8 Quarters

Analyst Consensus — 6 Analysts

6Buy

Consensus RatingBuy# Analysts6Avg. Consensus PT$31Upside to Avg. PT+425.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 2, 2026	Cantor Fitzgerald	Josh Schimmer	Maintained	Overweight	$40
Jun 8, 2026	Needham	Gil Blum	Maintained	Buy	$41
May 12, 2026	Needham	Gil Blum	PT Raise	Buy	$18→$41
May 11, 2026	Cantor Fitzgerald	Josh Schimmer	PT Raise	Overweight	$10→$40
May 11, 2026	Wedbush	Martin Fan	PT Raise	Outperform	$23→$40
May 8, 2026	HC Wainwright & Co.	Emily Bodnar	PT Raise	Buy	$15→$35
May 4, 2026	Needham	Gil Blum	Maintained	Buy	$18
Mar 11, 2026	Needham	Gil Blum	Maintained	Buy	$18
Nov 12, 2025	HC Wainwright & Co.	Emily Bodnar	PT Raise	Buy	$12→$15
Oct 17, 2025	Wedbush	Martin Fan	PT Raise	Outperform	$18→$23
Oct 17, 2025	Needham	Gil Blum	Maintained	Buy	$18
Jun 11, 2025	HC Wainwright & Co.	Emily Bodnar	Assumes	Buy	$12
May 15, 2025	Needham	Gil Blum	PT Cut	Buy	$23→$18
Apr 8, 2025	Needham	Gil Blum	Maintained	Buy	$23
Mar 26, 2025	HC Wainwright & Co.	Edward White	Maintained	Buy	$20
Mar 25, 2025	Wedbush	Martin Fan	Maintained	Outperform	$18
Mar 25, 2025	Cantor Fitzgerald	Josh Schimmer	PT Cut	Overweight	$23→$20
Mar 25, 2025	Needham	Gil Blum	Maintained	Buy	$23
Dec 30, 2024	HC Wainwright & Co.	Edward White	Initiate	Buy	$20
Nov 13, 2024	Needham	Gil Blum	Maintained	Buy	$23

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Cantor Fitzgerald Reiterates Overweight on Artiva Biotherapeutics, Maintains $40 Price Target

Cantor Fitzgerald analyst Josh Schimmer reiterates Artiva Biotherapeutics (NASDAQ:ARTV) with a Overweight and maintains $40 price target.

Benzinga Newsdesk

PRO
Needham Reiterates Buy on Artiva Biotherapeutics, Maintains $41 Price Target

Needham analyst Gil Blum reiterates Artiva Biotherapeutics (NASDAQ:ARTV) with a Buy and maintains $41 price target.

Benzinga Newsdesk

PRO
Needham Maintains Buy on Artiva Biotherapeutics, Raises Price Target to $41

Needham analyst Gil Blum maintains Artiva Biotherapeutics (NASDAQ:ARTV) with a Buy and raises the price target from $18 to $41.

Benzinga Newsdesk

PRO
Cantor Fitzgerald Maintains Overweight on Artiva Biotherapeutics, Raises Price Target to $40

Cantor Fitzgerald analyst Josh Schimmer maintains Artiva Biotherapeutics (NASDAQ:ARTV) with a Overweight and raises the price target from $10 to $40.

Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Artiva Biotherapeutics, Raises Price Target to $40

Wedbush analyst Martin Fan maintains Artiva Biotherapeutics (NASDAQ:ARTV) with a Outperform and raises the price target from $23 to $40.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Artiva Biotherapeutics, Raises Price Target to $35

HC Wainwright & Co. analyst Emily Bodnar maintains Artiva Biotherapeutics (NASDAQ:ARTV) with a Buy and raises the price target from $15 to $35.

Benzinga Newsdesk

Artiva Biotherapeutics Inc

Artiva Biotherapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Cantor Fitzgerald Reiterates Overweight on Artiva Biotherapeutics, Maintains $40 Price Target

PRO
Needham Reiterates Buy on Artiva Biotherapeutics, Maintains $41 Price Target

PRO
Needham Maintains Buy on Artiva Biotherapeutics, Raises Price Target to $41

PRO
Cantor Fitzgerald Maintains Overweight on Artiva Biotherapeutics, Raises Price Target to $40

PRO
Wedbush Maintains Outperform on Artiva Biotherapeutics, Raises Price Target to $40

PRO
HC Wainwright & Co. Maintains Buy on Artiva Biotherapeutics, Raises Price Target to $35

People Also Watch

People Also Watch

Artiva Biotherapeutics Inc

Artiva Biotherapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROCantor Fitzgerald Reiterates Overweight on Artiva Biotherapeutics, Maintains $40 Price Target

PRONeedham Reiterates Buy on Artiva Biotherapeutics, Maintains $41 Price Target

PRONeedham Maintains Buy on Artiva Biotherapeutics, Raises Price Target to $41

PROCantor Fitzgerald Maintains Overweight on Artiva Biotherapeutics, Raises Price Target to $40

PROWedbush Maintains Outperform on Artiva Biotherapeutics, Raises Price Target to $40

PROHC Wainwright & Co. Maintains Buy on Artiva Biotherapeutics, Raises Price Target to $35

People Also Watch

People Also Watch

PRO
Cantor Fitzgerald Reiterates Overweight on Artiva Biotherapeutics, Maintains $40 Price Target

PRO
Needham Reiterates Buy on Artiva Biotherapeutics, Maintains $41 Price Target

PRO
Needham Maintains Buy on Artiva Biotherapeutics, Raises Price Target to $41

PRO
Cantor Fitzgerald Maintains Overweight on Artiva Biotherapeutics, Raises Price Target to $40

PRO
Wedbush Maintains Outperform on Artiva Biotherapeutics, Raises Price Target to $40

PRO
HC Wainwright & Co. Maintains Buy on Artiva Biotherapeutics, Raises Price Target to $35